Cite
HARVARD Citation
Stamatoullas, A. et al. (2022). Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. Leukemia & lymphoma. 63 (13), pp. 3063-3071. [Online].